916210-33-8 Usage
Uses
Used in Pharmaceutical Industry:
Tert-butyl ((2-(trifluoromethyl)pyridin-4-yl)methyl)carbamate serves as a building block for the development of pharmaceutical drugs. Its unique structure and properties contribute to the creation of novel therapeutic agents, potentially leading to advancements in medicine.
Used in Agrochemical Industry:
In the agrochemical field, tert-butyl ((2-(trifluoromethyl)pyridin-4-yl)methyl)carbamate is utilized as a component in the synthesis of agrochemicals. Its role in this industry is crucial for developing new pesticides and other agricultural products to improve crop protection and yield.
Used in Materials Science:
Tert-butyl ((2-(trifluoromethyl)pyridin-4-yl)methyl)carbamate also has potential applications in materials science. Its distinctive molecular structure may contribute to the development of new materials with specific properties for various uses.
Used as a Reagent in Chemical Reactions:
Furthermore, tert-butyl ((2-(trifluoromethyl)pyridin-4-yl)methyl)carbamate functions as a reagent in chemical reactions. Its participation in these processes can facilitate the synthesis of complex organic compounds and contribute to the advancement of chemical research.
Overall, the diverse applications of tert-butyl ((2-(trifluoromethyl)pyridin-4-yl)methyl)carbamate across different industries highlight its significance and potential in scientific and industrial development.
Check Digit Verification of cas no
The CAS Registry Mumber 916210-33-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,6,2,1 and 0 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 916210-33:
(8*9)+(7*1)+(6*6)+(5*2)+(4*1)+(3*0)+(2*3)+(1*3)=138
138 % 10 = 8
So 916210-33-8 is a valid CAS Registry Number.
916210-33-8Relevant academic research and scientific papers
COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS
-
, (2019/10/29)
The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5-adenosine monophosphate (cAMP).
